Stock analysis, price data, and AI-powered insights for Boston Scientific (BSX).
Boston Scientific operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BSX.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BSX Stock Intelligence Report. [stoxpulse.com/stocks/bsx]
Disclaimer: The information on this page about Boston Scientific (BSX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Boston Scientific.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 1%
Mar 31
Mahoney sold 387K shares
May 28
Pegus bought 2K shares
May 20
BTIG Reiterates Buy on Boston Scientific, Maintain...
1d ago
If You’re Looking for the ‘Next Big Thing’ Before ...
1d ago
StoxPulse AI results for BSX: Pulse Score 50/100. Primary sentiment trends from 13 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$69.74B
P/E Ratio
48.9
EPS
$0.45
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+2.5%
Sep 25
+4.1%
Dec 25
+1.6%
Mar 26
+0.7%
Beat estimates 4 of 4 quarters (100%)
Sector
Healthcare
Industry
Health Care Equipment
BTIG Reiterates Buy on Boston Scientific, Maintains $65 Price Target
If You’re Looking for the ‘Next Big Thing’ Before the OpenAI and Anthropic IPOs, Try This Barchart Stock Screener
Why Did ADBE, CHWY, BSX Slump To 52-Week Lows Last Week?
Truist Reiterates Buy Rating for Boston Scientific (BSX)
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke
Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One